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Abstract 
Class IA phosphoinositide 3-kinases (PI3K) are essential to function of normal and 
tumor cells, and modulate immune responses. T lymphocytes express high levels of 
p110 and p110 class IA PI3K. Whereas the function of PI3K p110 in immune and 
autoimmune reactions is well established, the role of p110 is less well understood.  
Here, a novel dual p110/ inhibitor (ETP-46321) and highly specific p110 (A66) or 
p110 (IC87114) inhibitors have been compared concerning T cell activation in vitro, as 
well as the effect on responses to protein antigen and collagen-induced arthritis in vivo. 
In vitro activation of naive CD4
+
 T lymphocytes by anti-CD3 and anti-CD28 was 
inhibited more effectively by the p110 inhibitor than by the p110 inhibitor as 
measured by cytokine secretion (IL-2, IL-10, and IFN-), T-bet expression and NFAT 
activation. In activated CD4
+
 T cells re-stimulated through CD3 and ICOS, IC87114 
inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN- 
better than A66. The p110/ inhibitor ETP-46321, or p110 plus p110 inhibitors also 
inhibited IL-21 secretion by differentiated CD4
+
 T follicular (Tfh) or IL-17-producing 
(Th17) helper cells. In vivo, therapeutic administration of ETP-46321 significantly 
inhibited responses to protein antigen as well as collagen-induced arthritis, as measured 
by antigen-specific antibody responses, secretion of IL-10, IL-17A or IFN-, or clinical 
symptoms. 
Hence, p110 as well as p110 Class IA PI3Ks are important to immune regulation; 
inhibition of both subunits may be an effective therapeutic approach in inflammatory 
autoimmune diseases like rheumatoid arthritis. 
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1. Introduction 
Class I phosphoinositide 3-kinases (PI3K) phosphorylate the 3 position of 4,5-
biphosphate phosphoinositides located in cell membranes. This produces 
phosphatidylinositide 3,4,5-triphosphate (PIP3) allowing the binding of proteins 
possessing pleckstrin homology (PH) domains. The recruited proteins are then activated 
to start metabolic cascades essential to different aspects of cell growth, proliferation, 
survival, differentiation, and migration [1-3]. Consequently, they are also essential to 
the development of normal and pathologic immune responses, including organ-specific 
or systemic autoimmune diseases like rheumatoid arthritis and systemic lupus 
erythematosus [4-7].  
Class I PI3K are heterodimers formed by regulatory and catalytic subunits; recruitment 
of regulatory subunits serve to bring the catalytic subunits close to the membranes were 
both PI3K activators and substrates are located. The nature of regulatory subunits 
further differentiates class I PI3K into class IA and class IB: Class IA catalytic isoforms 
(p110, p110 and p110) form heterodimers with the regulatory subunits p85, p55, 
p50, p85, and p55; activation is characteristically dependent on regulatory subunit 
recruitment to Tyr-phosphorylated Y-x-x-M sequence motifs. Class IB catalytic 
subunits (p110) bind regulatory subunits p101 and p84/p87; they are activated upon 
binding of their regulatory subunits to G-protein coupled receptors (GPCR). 
Class I PI3K subunits have oncogenic potential; and particularly the p110 catalytic 
isoform is frequently mutated in different cancer cells [8]. Hence, PI3K inhibitors have 
been actively pursued as anti-cancer drugs. However, their impact on the immune 
system should be also carefully determined, in first place, because the importance of 
PI3K in the development of immune reactions confers an immunotherapeutic potential 
on PI3K inhibitors; secondly, because the overall impact of these inhibitors in tumor 
immunity needs to be determined [9]. 
Whereas the expression of p110 and p110 catalytic subunits is wide, the p110 and 
p110 polypeptides are mainly expressed in hematopoietic cells including T and B 
lymphocytes. Indeed, genetic and pharmacological data show that both the class IA 
p110 and the class IB p110 subunits are essential to adequate development, activation 
and differentiation of B and T lymphocytes, as well as interesting targets for therapy in 
immunopathology or cancer immunotherapy [5, 7, 10-12]. When T and B lymphocytes 
are considered, class IA p110 catalytic subunits have specific functions in signaling 
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through the antigen receptor, amplification of signals by B cell or T cell costimulatory 
molecules (i.e., CD19, CD28, ICOS (CD278, also called H4 [13]), through TNF family 
molecules, or cytokine receptors. 
Among Class IA PI3Ks, T lymphocytes express high levels of p110 and p110 
catalytic subunits and comparatively low levels of p110 [14]. Intriguingly, p110 
binds better than p110 to PI3K regulatory subunits, and consequently it is more 
efficiently recruited to costimulatory molecules like CD28 and ICOS [14], suggesting 
that p110 might play a relevant role in T lymphocyte function. 
However, the data on the role of p110 in lymphocyte function are scarce, in part 
because of the embryonic lethality of p110-deficient mice, in part because of the 
relative non-specificity of some p110 inhibitors [15, 16]. Still, specific silencing [14] 
or the use of highly specific inhibitors of p110 like A66 [17] show a clear, if minor, 
role of p110 on B cell and T cell activation. Here, the effect of ETP-46321, a dual 
inhibitor of the p110 and p110 PI3K isoforms [18, 19] has been compared to the 
effect of highly specific p110- or p110-specific inhibitors (IC87114 and A66, 
respectively). We show that ETP-46321 shares the characteristics of both inhibitors, and 
is a strong inhibitor of lymphocyte proliferation and the secretion of cytokines essential 
to antibody or inflammatory responses.  
Rheumatoid arthritis (RA) is a systemic, inflammatory, autoimmune disease 
characterized by uncontrolled inflammation of the joints and the presence of 
autoantibodies directed against multiple autoantigens. Its precise etiology is unknown, 
yet T lymphocytes intervene in the pathogenic process, as shown by the presence of T 
cells in the inflammatory infiltrate of affected joints and the strong association of the 
disease with molecules involved in T cell activation [20]. Furthermore, blockade of 
CD28-dependent T-cell costimulation by abatacept (CTLA-4Ig) has provided a 
successful therapy for RA [21, 22]. 
Its relatively high incidence among the general population (approximately 1% 
worldwide) makes RA an important target for drug discovery. The animal model of 
collagen-induced arthritis (CIA) reproduces many features of human RA and is widely 
used to assess the effects of potential novel therapies [23]. 
The fact that p110 PI3K contributes significantly to antigen activation of antibody 
producing B lymphocytes, but both the p110 and p110 PI3K isoforms participate in 
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B lymphocyte development in the bone marrow and in B cell survival in the periphery 
[24] adds interest to the study of dual p110 and p110 PI3K inhibitors in RA.  
Our data indicate that therapeutic administration of ETP-46321 can be successfully used 
in vivo to inhibit secretion of antigen-specific antibodies and effector cytokines in 
response to protein antigen as well as in mice undergoing collagen-induced arthritis. 
Thus, PI3K inhibitors like ETP-46321 can be candidate drugs to treat abnormal adaptive 
immune responses, including autoimmune diseases where CD4
+
 T lymphocytes and 
antibody responses have a prime role. 
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2. Materials and Methods 
 
2.1. Mice 
C57BL/6 mice aged 8-16 weeks were used throughout this study. They were bred in the 
animal care facility of the Centro de Investigaciones Biológicas under specific 
pathogen-free conditions. For the collagen-induced arthritis experiments, female 
DBA/1OlaHsd mice were purchased from Harlan Laboratories (Horst, The 
Netherlands). They were housed in the animal facility of the Centro Nacional de 
Microbiología, Instituto de Salud Carlos III, in seal-safe cages under air flow supply. 
All the experimental procedures were performed according to established institutional 
and national guidelines. 
 
2.2. Inhibitors 
The PI3K/ inhibitor ETP-46321 was synthesized by the Experimental Therapeutics 
Programme, Spanish National Cancer Research Centre (CNIO), as described [18, 19]. 
PI3K inhibitor A66 was from Selleck Chemicals (Houston, Texas); PI3K inhibitor 
IC87114 was from Symansis Pty. (Timaru, New Zealand); LY 294002 was from Sigma-
Aldrich (Saint Louis, Missouri). Some characteristics of these inhibitors are 
summarized in Table 1. 
 
2.3. T lymphocyte isolation and activation 
To obtain naive CD4
+
 T lymphocytes (CD4
+
CD62L
+
 T cells), spleens were passed 
through a 70 m mesh. After centrifugation, red blood cells were lysed and the cells 
washed in culture medium (Click’s medium supplemented with 10% heat inactivated 
FCS). Then, naive CD4
+
 T cells were isolated using Miltenyi CD4
+
CD62L
+
 T cell 
isolation kit II for mouse cells (Ref. 130-093-227, Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturers’ instructions. The isolated cells were 
routinely >97% CD4
+
, >95% CD62L
+
. Cells (10
6
) were cultured in 1 ml culture 
medium in 24-well culture plates (Costar) pre-coated with anti-CD3 antibody (YCD3-1 
[30], 5 g ml-1). Where indicated, anti-CD28 (H57, 2.5 g ml-1, eBioscience, San 
Diego, California), DMSO or inhibitors dissolved in DMSO (1 l per culture) were 
added. At 24h, the cultures were resuspended, centrifuged and the supernatants assayed 
for cytokine content. 
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To obtain IL-2-expanded CD4
+
 T cell blasts, CD4
+
 T cells were isolated from spleen 
cell suspensions after red cell lysis using the Miltenyi CD4
+
 T cell isolation kit for 
mouse (Ref. 130-090-860, Miltenyi Biotec) according to the manufacturers’ 
instructions. The isolated cells were routinely >95% CD4
+
 and were activated for 48h 
(10
6
 ml
-1
) with Concanavalin A (ConA, Sigma-Aldrich, 3 g ml-1) with mitomycin-C 
(Sigma-Aldrich) treated T-cell depleted spleen cells (APC, 0.5x10
6
 ml
-1
) plus IL-2 
(PeproTech, Rocky Hill, New Jersey), isolated in Percoll gradient, and expanded for 
two days in IL-2-containing medium (4-days, ConA-induced, IL-2 expanded CD4
+
 T 
cell blasts) as described previously [31]. The resulting blasts were washed and activated 
for further 24h (0.5-1x10
6
 ml
-1
) in fresh medium with plate bound anti-CD3 (YCD3-1, 
10 g ml-1) and anti-ICOS (Anti-H4 C398.4A [13, 32], 20 g ml-1) or control 
antibodies. Th17 and Tfh cells were generated from naive CD4
+
 T cells activated with 
ConA for 4 days under conditions favoring the differentiation of Th17 cells (anti-IL-4 
antibody 11B11, 5 g ml-1; anti-IFN- antibody XMG1, 10 g ml-1; IL-6 (PeproTech) 
20 ng ml
-1
, IL-23 (PeproTech) 20 ng ml
-1
, TGF- (R&D Systems Europe, Abingdon, 
UK) 5 ng ml
-1
), or Tfh cells (anti-IL-4 antibody 11B11, 5 g ml-1; anti-IFN- antibody 
XMG1, 10 g ml-1; IL-6 20 ng ml-1). The cells were then re-activated for 24h as 
described above for IL-2 blasts. In the experiments described in Figures 3c and 4c, 10
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Th17 or Tfh cells were mixed with an equal number of antibody-coated latex beads 
(Anti-CD3, 10 g ml-1 plus anti-ICOS or control antibodies at 20 g ml-1) [31]. After 
overnight culture in 1 ml of complete culture medium in round-bottom 5 ml polystyrene 
tubes, the tubes were centrifuged and the supernatant taken for cytokine analysis.  
The secreted cytokines were determined with Ready-Set-Go!
®
 capture ELISA kits 
(eBioscience) specific for mouse IL-2, IL-10, IL-17A, IL-21, IFN-, or TNF-, or as 
described in [31] (mouse IL-4). All antibodies used were obtained and purified in our 
laboratory unless stated otherwise. 
 
2.4. Nuclear extracts, cell lysates and immunoblot 
To obtain nuclear extracts, naive CD4
+
 T lymphocytes (2-3x10
6
 ml
-1
 in 24-well culture 
plates) were activated overnight with anti-CD3 and anti-CD28 antibodies. The cells 
were resuspended, and nuclear extracts were obtained as described in detail in [33]. The 
extracts were separated by SDS-PAGE, and immunoblotted with rabbit antibodies to 
NFATc1 (sc-13033, Santa Cruz Biotechnology, Dallas, Texas) as previously described 
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in [14]. As a load control, part of the same gel was cut and silver stained, as described in 
[34]. 
To detect phosphorylated proteins in cell lysates, four day CD4
+
 Tfh cells were washed 
with PBS and activated for 20 min in serum-free medium at 40x10
6
 cells ml
-1
 by mixing 
with an equal number of latex beads previously coated with antibodies (Anti-CD3, 10 
g ml-1 plus anti-ICOS or control antibodies at 20 g ml-1), as described [31]. PI3K 
inhibitors were added to cells 10 min before activation. The reaction was stopped by 
adding excess ice-cold PBS, 500 µM EDTA, 200 µM NaVO4. After centrifugation, the 
cells were lysed for 15 min on ice at 2x10
7
 cells ml
-1
 in Triton X-100 lysis buffer (1% 
Triton X-100, 50 mM Tris/HCl, 150 mM NaCl, pH 7.6 containing 1mM MgCl2, 1 mM 
EGTA, 10 g ml-1 aprotinin, 10 g ml-1 leupeptin, 1 mM PMSF, and 1 mM NaVO4). 
Cell lysates were centrifuged, and post-nuclear lysates were mixed v:v with 2x reducing 
SDS Laemmli sample buffer. Separation of proteins by SDS-PAGE, and immunoblot 
with anti-phosphoSer
473
Akt (Cell Signaling Technology, Danvers, Massachusetts, 
#4060), anti-phosphoThr
308
Akt (Cell Signaling Technology, #13038) or anti-phospho-
ERK (Cell Signaling Technology) were performed as described previously [14]. Load 
controls were performed using polyclonal rabbit anti-Akt or anti-Erk antibodies [31]. 
 
2.5. T-bet expression 
T-bet expression was determined by flow cytometry in naive CD4
+
 T lymphocytes 
before or after overnight activation in 24-well plates with plate-bound anti-CD3 plus 
anti-CD28 antibodies, as described above. Cells were resuspended, washed, fixed and 
permeabilized with the Transcription Factor Staining Buffer Set 
(Affimetrix/eBioscience). Then, the cells were stained with anti-human T-bet-PE 
(eBioscience 12-5825) or control isotype antibody according to the protocol for 
intracellular staining of transcription factors. Cells were then analyzed in a FC-500 flow 
cytometer (Beckman Coulter, Brea, California). 
 
2.6. Immunization with KLH protein 
100 g of keyhole limpet hemocyanin (KLH) in Freund’s complete adjuvant (both from 
Sigma-Aldrich) were injected s.c. in two sites in the base of the tail. ETP-46321 
suspended in 0.5% carboxymethyl cellulose, 20% sucrose in water, or vehicle, was 
administered by oral gavage (20 mg kg
-1
) on days 3 to 6 after KLH injection. On day 7, 
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mice were bled to obtain the serum, sacrificed, and the spleen and the draining inguinal 
lymph nodes were extracted. Cell suspensions were obtained and used to determine total 
cell counts and lymphocyte subpopulations. In addition, lymph node cells from 
individual mice (2x10
6
cells per culture) were re-activated in vitro in 1 ml of culture 
medium with or without KLH (100 g ml-1) in round-bottom 5 ml polystyrene tubes. 
After three days, culture supernatants were taken, and live cells assessed with an MTT 
assay, as described [35]. Cytokine content in the supernatants was determined by 
ELISA as describe above. Serum anti-KLH specific antibodies of the IgM, IgG1, 
IgG2b, and IgG3 subclasses were determined by ELISA in 96-well ELISA plates 
(Costar Life Sciences, Tewksbury, Massachusetts) coated with KLH (20 g ml-1 in 
borate saline) and horseradish peroxidase-coupled goat anti-mouse Ig class-specific 
antibodies (Southern Biotech, Birmingham, Alabama). Serum titer was calculated as the 
reciprocal of the dilution giving 50% of maximal optical density. 
 
2.7. Collagen-induced arthritis: Induction, assessment, and treatment 
DBA/1OlaHsd mice were immunized intradermally under anesthesia at the base of the 
tail with an emulsion of chicken type II collagen in Freund’s complete adjuvant (200 g 
per mouse) essentially as described previously in [36]. Clinical symptoms of arthritis 
were assessed daily by scoring each limb of the mice according to the following criteria: 
0 normal, 1 slight swelling and erythema, 2 pronounced edematous swelling, and 3 joint 
rigidity. The degree of joint swelling for each paw (scored from 0 to 3) was assessed 
and expressed as the cumulative arthritis severity score for 4 paws, with a maximum 
possible clinical score of 12 per mouse. Arthritis onset (the first day in which clinical 
signs of arthritis were observed) appeared at 3-5 weeks after immunization. Graphs 
were used to represent the change in clinical score in relation to the day of onset.  
Mice showing an illness score equal to or higher than 1 in one paw were randomly 
assigned to the experimental groups. Mice were treated daily during 11 days with ETP-
46321 suspended in 10% Dimethylpirrolydone (DMP, Sigma-Aldrich) pH-3/90% 
PEG300 (Sigma-Aldrich), at a dose of 20 mg/kg body weight per mouse. Oral 
administration of the same vehicle was used as a control. The day after the last 
administration of ETP-46321, the mice were bled to obtain sera and sacrificed to obtain 
inguinal lymph nodes.  
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2.8. Analysis of type II collagen–specific responses.  
Single cell suspensions of draining inguinal lymph nodes from individual mice were 
prepared and cultured (2x10
5
/200 l) in the presence or absence of 50 g/ml chicken 
type II collagen. After 48 hours, 100 l of the supernatant was collected to measure 
cytokine production by ELISA. 24 hours later, proliferation in the remaining cell 
cultures was evaluated by WST-1 Cell Proliferation Assay Kit from Roche Applied 
Science (Penzberg, Germany) as indicated by manufacturer´s instructions. IFN- and 
IL-17A were quantified with mouse Ready-Set-Go!
®
 capture ELISA kits (eBioscience). 
Collagen-specific antibodies in the serum were measured by ELISA, as described for 
anti-KLH antibodies, using 96-well plates coated with 2 g/ml of chicken type II 
collagen in PBS. 
 
2.9. Statistical analysis 
The statistical significance of differences was calculated with the Student’s t test, or the 
Mann Whitney test, using the Excel (Microsoft Corporation, Redmond, Washington) or 
GraphPad Prism 4 (GraphPad Software, Inc, La Jolla, California) applications. 
Differences with P values ≤0.05 were considered significant. 
 
 
3. Results 
 
3.1 Effect of ETP-46321 on the activation of naive CD4
+
 T lymphocytes 
The effect of the dual p110 and p110 PI3K inhibitor ETP-46321 on the activation of 
naive CD4
+
 T lymphocytes by anti-CD3 plus anti-CD28 was assessed and compared to 
the effect of inhibitors specific for the p110 (A66) and p110 (IC87114) subunits 
(Figure 1a-d). TCR/CD3 activation of these cells is strongly dependent on 
costimulation by CD28, a molecule that recruits and activates class IA PI3K. In these 
assays, ETP-46321 significantly inhibited IL-2, IL-10 and IFN- secretion after 24h of 
culture (Figure 1a-c) or cell proliferation at 72h (data not shown). Of note, IFN- 
secretion was ten-fold more sensitive to inhibition than IL-2, and more than fifty fold 
than IL-10 secretion (Figure 1a-c, summarized in Table 2). Differences among 
cytokines concerning their sensitivity to inhibitors were also found using the p110 
inhibitor IC87114, yet IL-10 secretion was not significantly inhibited. The p110 
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inhibitor A-66 had a lower but significant effect in this assay (Figure 1a-c), fitting with 
our recent data showing efficient association of the p110 subunit to CD28 [14]. The 
high sensitivity of IFN- to all PI3-K inhibitors correlated with a strong inhibition of T-
bet induction, the main transcription factor for IFN- secretion (Figure 1d).  
Costimulatory molecules like CD28 and ICOS mediate part of their costimulatory 
effects through a PI3-kinase-, Itk-, phospholipase C1-, and Ca2+ flux-dependent 
activation of NFATc1 resulting in its nuclear translocation [37]. Consequently, the 
effect of ETP-46321 on the presence of NFATc1 in nuclear extracts was compared to 
that of p110- and p110-specific inhibitors. The activation of NFATc1 was slightly 
inhibited by the p110-specific inhibitor A66, and strongly by the p110-specific 
inhibitor IC-87114. Yet, the dual inhibitor ETP-46321 was the most effective at 
blocking NFATc1 activation (Figure 1e). 
 
3.2. Effect of ETP-46321 on cytokine secretion by activated CD4
+
 T cells 
As a potential immunotherapeutic agent, it was also important to determine the effect of 
ETP-46321 or the p110 and p110 inhibitors on the function of activated, effector 
CD4
+
 T cells. The effect of ETP-46321 on cytokine secretion by activated T cells “in 
vitro” was firstly assessed using ConA-activated, IL-2 expanded CD4+ T blasts. They 
were then reactivated with anti-CD3 antibody alone or, as these activated cells express 
the CD28-like, PI3K-binding costimulatory molecule ICOS, they were also activated by 
anti-CD3 plus anti-ICOS antibodies. ICOS costimulation enhanced secretion of some 
cytokines (IL-2, IL-4, IL-17A, IFN-), but not others (IL-10, Figure 2). 
ETP-46321 efficiently inhibited all the cytokines analyzed in culture supernatants after 
24 h of blast reactivation (IL-2, IL-4, IL-10, IL-17A, and IFN-), and particularly IL-2, 
IL-4, IL-17A, and IFN- (Figure 2, Table 2). The p110 inhibitor IC87114 showed a 
similar profile, except for inhibition of IL-17A and IL-10, that was clearly less efficient 
(Figure 2, Table 2). 
In this assay, the p110 inhibitor A66 needed micromolar concentrations to achieve 
significant inhibition of cytokine secretion, and was poor as an inhibitor of IL-10 
(Figure 2). These data suggest that, in these cells, most cytokines depend more on 
p110 than on p110; on the other hand IL-10 secretion might be dependent on 
different PI3K isoforms. 
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3.3. Effect of p110 and p110 inhibition on IL-21 secretion by Th17 and Tfh effector 
cells 
IL-21 is essential to germinal centre formation and antibody production that is 
supported by Th17 cells and Tfh cells [38]. Since IL-21 is produced in an ICOS- and 
PI3K-dependent fashion [39, 40], its production was investigated in the CD4
+
 blasts 
described above. However IL-21 levels were barely detectable in the IL-2-expanded, 
ConA-induced cells used, this could be due to an inhibitory effect of IL-2 [41]. Hence, 
to compare the effect of ETP-46321 and isoform-specific PI3K inhibitors on IL-21 
secretion we used cells previously differentiated for four days into Th17 or Tfh cells 
(Figures 3, 4, Table 2). Both types of cells, and particularly Tfh cells, expressed high 
levels of ICOS in their surface. As shown in Figure 3a, differentiated Th17 cells 
produced much higher amounts of IL-17A than the IL-2 blasts cells depicted in Figure 
2d, and IL-21 levels were clearly detectable (Figure 3b). IL-17A secretion was 
enhanced by ICOS costimulation, and was inhibited by all the PI3K inhibitors at 
concentrations two to five-fold lower than those observed in CD4
+
 IL-2 blasts (compare 
Figure 2d, Figure 3a, see also Table 2). Yet, the pattern of IL-17A sensitivity to ETP-
46321 or the p110 (A66) and p110 (IC87114) inhibitors was similar to that 
previously observed in IL-2 blasts (Figure 3a, compare to Figure 2d). 
IL-21 production was not enhanced by ICOS costimulation in differentiated Th17 cells 
(Figure 3b). ETP-46321 inhibited IL-21 secretion, although at micromolar rather than 
the nanomolar concentrations that inhibited IL-17A secretion. In contrast, IL-21 
secretion was not significantly inhibited either by A66 or by IC87114 (Figure 3b, 
Table 2), suggesting that both p110 and p110 contribute to IL-21 secretion in these 
differentiated cells. This was confirmed in experiments where Th17 cells were activated 
in the presence of the p110- and p110-specific inhibitors A66 and IC87114 alone or 
combined; only the combination of both inhibitors significantly diminished IL-21 
levels, as did the dual inhibitor ETP-46321 (Figure 3c). When the levels of IL-17A 
were analyzed, A66 and IC87114 showed an additive effect. 
We also set up experiments in Tfh-differentiated cells that express high levels of ICOS 
to determine whether ICOS enhanced early signals like Akt and MAPK activation or 
cytokine secretion in these IL-21 producing cells, as well as the role of PI3K in these 
events. As shown in Figure 4a, Akt phosphorylation in Ser
473
 and Thr
308
 induced by 
CD3 re-activation of differentiated Tfh cells was efficiently enhanced by ICOS 
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costimulation, as did MAPK (Erk) activation. Inhibition of p110 by IC87114 clearly 
inhibited Akt or Erk phosphorylation, yet the dual inhibitor ETP-46321 was an even 
more efficient inhibitor of these parameters. The p110 inhibitor A66 did not induce 
significant effects on Akt or Erk phosphorylation in these cells (Fig. 4a). 
As in other activated cells expressing ICOS, in Tfh cells ICOS ligation significantly 
enhanced CD3-induced secretion of IL-17A, but not the secretion of IL-21. As observed 
in CD4
+
 IL-2 blasts or Th17 cells, ETP-46321 significantly inhibited secretion of both 
IL-17A and IL-21 in Tfh (Fig. 4b). As in Th17 cells, in Tfh cells the p110- and p110-
specific inhibitors A66 and IC87114 significantly inhibited IL-17A, but not IL-21 
secretion(Fig. 4b, and Table 2). 
 
3.4. ETP-46321 inhibits ongoing immune responses to protein antigen “in vivo” 
Oral treatment with ETP-46321 is effective in vivo as an antitumoral, and has well 
established pharmacokinetic properties, low "in vivo" clearance and good oral 
bioavailability [18, 19]. In view of its effects on lymphocyte activation “in vitro”, 
experiments were set out to determine the ability of ETP46321 to inhibit immune 
responses “in vivo”. Mice were immunized with the protein antigen KLH. After three 
days, the mice were orally administered ETP-46321 for four days at doses (20 mg kg
-1
) 
that achieve micromolar concentrations in the serum [19], according to the schedule 
summarized in Figure 5a. The day after the last administration of ETP-46321, serum 
was collected and cells from the spleen and draining lymph nodes were obtained. The 
total number of cells in the spleen or lymph nodes was not significantly different in the 
ETP-46321-treated mice, nor was the percentage of different T and B lymphocyte 
subpopulations as determined by flow cytometry, including total B lymphocytes 
(CD19
+
 cells) or germinal center (CD19
+
PNA
+
) B cells, total T lymphocytes (CD3
+
 
cells), CD4
+
 and CD8
+
 T cells, Treg cells (CD3
+
CD4
+
Foxp3
+
), Tfh 
(CD3
+
CD4
+
CXCR5
+
ICOS
+
), or NK (CD3
-
CD16
+
) cells. 
We then checked the levels of anti-KLH antibodies in the sera of the immunized mice; 
IgM antibodies were significantly enhanced, whereas the IgG3 antibodies (that are 
largely dependent on IFN-) were significantly diminished in ETP-46321-treated mice. 
Antibody titers of the IgG1 and IgG2b isotypes were not significantly modified (Figure 
5b). To analyze the effect of ETP-46321 on antigen-specific proliferation and cytokine 
production, lymph node cells from individual mice were re-stimulated with KLH “in 
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vitro”. Proliferation or IL-2 secretion by antigen-activated cells from ETP-46321-treated 
mice was not significantly modified, yet secretion of IL-4, IL-10, IL-17A, or IFN- was 
significantly lower in these mice (Figure 5c). This confirms the potential of ETP-46321 
to control an ongoing immune response “in vivo”. 
 
3.5. ETP-46321 significantly inhibits collagen-induced arthritis 
Since ETP-46321 inhibits T-dependent antibody responses as well as the production of 
cytokines that are involved in the development of arthritis and other autoimmune 
diseases, we checked the effect of oral administration of ETP-46321 in a therapeutic 
fashion in a model of collagen-induced arthritis. Daily administration of ETP-46321 (20 
mg kg
-1
) or vehicle started once clear clinical symptoms appeared; mice that did not 
develop arthritis were not included in the assay. As shown in Figure 6, administration 
of ETP-46321 for 11 days significantly inhibited the development of clinical symptoms 
in treated mice as compared to mice treated with vehicle; these mice continued to 
increase the severity of arthritis. 
At the end of the treatment, mice were bled and checked for anti-collagen antibodies 
(Figure 6b). Total anti-collagen IgG antibody was lower in ETP-46321-treated mice 
than in vehicle-treated control mice, but the difference was not statistically significant. 
In contrast, anti-collagen antibody of the arthritis-relevant isotypes IgG1 and IgG2a was 
significantly lower in the mice treated with ETP-46321. 
Cells from the draining lymph nodes were reactivated with collagen and checked for 
antigen-specific proliferation and cytokine secretion "ex vivo". No significant 
differences in the number of cells recovered from the lymph nodes, the proportion of the 
main functional T and B lymphocyte subsets, or the proliferation induced by collagen 
were observed in ETP-treated mice (Figure 6c, and data not shown). Interestingly, 
collagen-induced IFN- secretion was clearly and significantly lower in ETP-46321 
treated mice (Figure 6c); IL-17A was also lower in ETP-46321-treated mice, but the 
difference was not significant. In contrast, proliferation or cytokine secretion in 
response to a polyclonal stimulus like anti-CD3 antibodies was not statistically 
significantly inhibited by ETP-463231 administration “in vivo” (data not shown). 
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4. Discussion 
Class I PI3-kinases are essential to different steps in the development of normal immune 
responses, including antigen activation of T and B lymphocytes and their expansion and 
differentiation into effector cells. In T cells, class IA PI3-kinases participate in antigen 
signaling through the TCR/CD3 complex as well as in costimulation by the CD28 
family molecules CD28 and ICOS. Class IA PI3K catalytic subunits (p110, p110, 
p110) are differentially expressed in distinct tissues. T lymphocytes and T cell lines 
have similar levels of the widely expressed p110 or the p110 catalytic subunit 
preferentially expressed by cells of hematopoietic origin [14]. Abundant genetic and 
pharmacological data show a major role of the p110 in the initiation and development 
of normal and pathological immune responses (reviewed in [3, 7, 10, 11]). Intriguingly, 
we have recently observed that p110 is the main catalytic isoform bound to the 
costimulatory molecules CD28 and ICOS through the recruitment of PI3K regulatory 
subunits [14]. This poses the question of the role of p110 in T cells.  
Analysis of p110 subunit’s role in immune responses has been hampered by the 
embryonic lethality of p110 deficiency, and by specificity problems of some p110 
inhibitors. Available data on the role of p110 in T cell function are scarce, but show 
that p110 silencing or inhibition induces low or moderate inhibition of cell viability 
[14, 28]. Proliferation and secretion of cytokines including IL-2, IL-4, or IFN- are also 
inhibited by p110-specific inhibitors [14, 17]. Early Akt phosphorylation was 
significantly inhibited by p110 silencing or inhibition, whereas p110 inhibitors had 
low effect on Erk activation, and p110 silencing enhanced Erk phosphorylation [14]. 
Here, we have extended this analysis to compare the effect of the p110 and p110 
inhibitors A66 and IC87114, or the dual inhibitor ETP-46321, on the activation of naive 
and activated CD4 T cells to secrete cytokines like IL-2 involved in T cell growth, or 
IL-10, IL-17A, IL-21, or IFN-, that are critically involved in the control of 
inflammation and antibody production (Figures 1-4, Table 2, and data not shown). 
Our titration of the PI-3 kinase inhibitors allowed a better assessment of the role of 
specific catalytic isoforms in the activation of naive T lymphocytes. CD28 
costimulation was necessary for effective activation of naive CD4
+
 T cells to proliferate 
or secrete IL-2, IL-10, and IFN-, or to induce the T-bet transcription factor essential to 
IFN- production. The p110 inhibitor A66 inhibited these parameters, albeit not as 
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effectively as IC87114; ETP-46321 was more effective than either inhibitor, in 
agreement with data showing that joint inhibition of p110 and p110 is more effective 
than p110 inhibition alone [14, 17]. Our results also show that IFN- secretion is 
clearly more sensitive to inhibition than cell growth or IL-2 secretion.  
Naive CD4
+
 T lymphocyte activation and differentiation into effector cells is mediated 
by CD28/ICOS and PI3K activation of NFAT in a Tec-kinase dependent pathway [37, 
42, 43]. As in other parameters, in NFAT activation we observed a low effect of p110 
inhibition, a clear effect of p110 inhibition, and an enhanced effect upon dual 
inhibition by ETP-46321. 
 
All these data indicate that ETP-46321 is a very efficient inhibitor of the initial steps of 
CD4
+
 T naive activation. To assess its suitability in immunotherapy, we went on to 
determine its effects on the effector phase of CD4
+
 T cell responses, as well as its 
possible advantages over p110- and p110-specific inhibitors. Particularly, we were 
interested in determining its effect on cytokine secretion by CD4
+
 T activated cells, 
including the secretion of IL-17 and IL-21 that characterize differentiated Th17 and Tfh 
cells, or the role of ICOS costimulation. CD28 and ICOS, as well as p110, are required 
for the differentiation of Th17 cells [44, 45]. On the other hand, ICOS and p110 PI3K 
are involved in IL-21 production by activated T cells and Tfh differentiation [39, 40, 46, 
47]. Th1, Th17, and Tfh contribute to autoimmune arthritis and other inflammatory 
diseases [48-50]. 
In activated cells, including Th17 and Tfh cells, ICOS clearly costimulated secretion of 
most cytokines assayed (IL-2, IL-4, IL-17A, or IFN-), but not IL-10 or IL-21 secretion 
(Figures 2-4). The effect of the different PI3-K inhibitors tested was similar in cultures 
activated or not in the presence of ICOS ligands. At the concentrations used, A66 
significantly inhibited all cytokines assayed except for IL-21, and was particularly 
effective on IL-2 and IFN- secretion, yet the p110 inhibitor IC87114 was roughly ten-
fold more effective. As in naive T cells, ETP-46321 was more effective than the 
isoform-specific inhibitors (Figures 2-4, summarized in Table 2). Interestingly, only the 
dual inhibitor ETP-46321 could significantly inhibit IL-21 secretion by Th17 or Tfh 
cells; furthermore, this effect was mimicked by combining the p110 and p110 
inhibitors, suggesting a non-redundant function of these PI3K subunits (Figure 4). 
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The fact that, unlike most cytokines, IL-21 secretion was not enhanced by ICOS 
costimulation, or significantly inhibited by the p110 inhibitor IC87114 was surprising 
as, in agreement with previous data [39, 51], we observed that ICOS clearly enhanced 
early activation of Akt, Erk, or IL-17 secretion in the same cells, that were significantly 
inhibited by IC87114. Previous reports show that IL-21 production by activated cells is 
fostered by ICOS costimulation in a PI3K-dependent way, with a relevant role for 
p110 [39, 40, 51, 52]. As IL-21 in these previous studies was analyzed in cells 
activated for two days, one possible explanation is that ICOS and p110 might be 
important for production during the early phases of differentiation of IL-21 producing 
cells, but not for already differentiated effector cells such as those used in our assays. In 
this regard, ICOS is essential for Tfh differentiation [38, 46, 47] in its early steps [53, 
54]. This might be due in part to enhanced IL-21 secretion during differentiation via 
enhanced NFATc activation by ICOS, as NFAT binding sites are present in the IL-21 
promoter [55]. 
As in IL-21, only the dual inhibitor ETP-46321significantly inhibited IL-10 secretion by 
activated, ICOS
+
CD4
+
 T cells. IL-10 is a peculiar cytokine because i) it can be secreted 
by different lymphocyte and leukocyte populations; ii) its secretion is controlled by 
many different signaling pathways and transcription factors; and iii) the weight of 
different signals and transcription factors in IL-10 secretion greatly vary among distinct 
leukocyte populations and lymphocyte subpopulations (see [56], for a review). Erk and 
c-Maf are involved in IL-10 secretion in most T lymphocytes, with variable contribution 
of other factors including STAT3,4 or 6, Jun, and SMAD. The reason(s) for the poor 
inhibition of IL-10 secretion by PI3-K inhibitors, as well as the need for dual p110 and 
p110 inhibition for partial suppression of IL-10 in these cells are unclear. Since p110 
inhibition alone is very efficient in blocking Erk activation in different mouse and 
human T cells ([14, 57], Figure 4), the effect of PI3-K inhibitors on pathways other than 
Erk needs to be further explored. 
 
As ETP-46321 inhibited IL-17A, IL-21, or IFN-, that are key players in autoimmune 
diseases like rheumatoid arthritis, SLE, or EAE [50], we determined its therapeutic 
potential in suppressing an ongoing immune response “in vivo” against the protein 
antigen KLH or collagen-induced arthritis. In the T-cell-dependent anti-KLH response, 
administration of ETP-46321 began on day three after immunization with KLH; at this 
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time the differentiation of effector cells like Tfh is close to its maximum [46, 53, 54, 
58]. In fact, we did not find significant differences in the number of Tfh cells in ETP-
46321-treated or –untreated, KLH-immunized mice (data not shown). In contrast, we 
found significantly diminished antibody responses to KLH of the IgG3 isoform. The 
effect of ETP-46321 on IgG3 might be due to inhibition of IFN- production, as IgG3 
production is dependent on IFN-, a cytokine that was clearly reduced in lymph node 
cells from ETP-46321-treated mice. Thus, ETP-46321 might also have an impact on 
IFN-- and IgG3-dependent autoimmune diseases like lupus nephritis [59, 60]. It should 
be noted that IFN-, ICOS, and PI3K play important roles in murine models of SLE or 
human lupus [50, 61-66]. IL-21 also plays a role in mouse models of lupus [62, 67], yet 
IL-21 levels in our cultures of cells from immunized mice were below the detection 
limits of the assay. Therapeutic treatments with ETP-46321 “in vivo” also inhibited IL-
17A. This raised the possibility of using ETP-46321 in autoimmune diseases where 
IFN-, IL-17 and PI3K have a prime role in the pathogenesis, including EAE [45], 
psoriasis [68], or rheumatoid arthritis [69, 70]. Indeed, oral administration of the dual 
inhibitor ETP-46321 significantly inhibited the clinical symptoms of collagen induced 
arthritis, the titer of pathogenic anti-collagen antibodies in serum, or the production of 
IFN- by collagen-activated lymph node cells.  
In summary, our data using specific inhibitors show that p110 is functionally the main 
class IA PI3K in CD28-dependent proliferation and differentiation of CD4
+
 T 
lymphocyte into cytokine-producing cells; similar effects were observed in already 
differentiated effector cells “in vitro”. By contrast, p110 has a variable, non-redundant 
role with p110 in T cell signaling and function, being more important to the function of 
activated CD4
+
 T cells. Clear differences among cytokines were observed when 
considering the role of ICOS, as well as concerning their sensitivity to inhibition by 
p110- or p110- specific PI3-kinase. The dual inhibitor ETP-46321 was clearly the 
most effective and produced a significant inhibition in most parameters considered, in 
agreement with the abundance of p110 and p110, but not p110, in lymphocytes. 
Furthermore, administration of the p110 and p110 PI3K inhibitor ETP-46321 to 
immunized mice significantly inhibited certain antibody and cytokine responses to a 
protein antigen, pointing to its potential as a therapeutic agent in autoimmune diseases, 
which was confirmed in a model of collagen-induced arthritis. 
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Figure Legends 
 
Figure 1. Impact of PI3-kinase inhibitors on the activation of T CD4
+
 naive 
lymphocytes. 
Naive (CD4
+
CD62L
+
) T lymphocytes were activated with anti-CD3 antibodies in the 
presence (closed squares) or absence (open squares) of soluble anti-CD28, or left 
unstimulated (triangles). PI3K inhibitors specific for p110 and p110 (ETP-46321), 
p110 (A66), or p110 (IC87114) were added, as indicated. After 24 h, the content of 
a) IL-2, b) IL-10, and c) IFN- in culture supernatants was determined by ELISA. Data 
are the mean ± SEM of triplicate samples from one representative experiment of three 
performed; *, significant differences (p <0.05, Student’s t-test) with samples with 
vehicle. In d) and e) the cells were activated for 16-24 h with anti-CD3 and anti-CD28 
antibodies plus inhibitors (5 M), as shown. In d), the presence of the T-bet 
transcription factor was determined by flow cytometry. In e), nuclear extracts were 
separated by SDS-PAGE and the NFATc1 nuclear factor detected by immunoblot. To 
assess the protein load, the lower part of the same SDS-PAGE gel was cut silver 
stained; The relative O.D. in each lane is plotted in the right panel.  
 
Figure 2. PI3-kinases p110 and p110 modulate the activation of T CD4+ blasts 
by TCR/CD3 stimulus and ICOS costimulus. 
ConA-induced, IL-2 expanded CD4
+
 T cell blasts were reactivated with anti-CD3 
antibodies in the presence (closed squares) or absence (open squares) of anti-ICOS 
antibodies as a costimulus. Results from unstimulated cultures are shown as open 
triangles. PI3K inhibitors (p110/p110, ETP-46321, p110, A66; p110, IC87114) 
were added, as indicated. After overnight culture, supernatants were analyzed by ELISA 
for cytokine content, as follows: a) IL-2, b) IL-4, c) IL-10, d) IL-17A, and e) IFN-. 
Data are the mean ± SEM of triplicate samples from one representative experiment of 
three performed; *, significant differences (p <0.05, Student’s t-test) with anti-CD3 plus 
anti-ICOS activated samples with vehicle. Triangles show data from unstimulated 
cultures. 
 
Figure 3. Effect of ICOS and PI3K inhibitors on cytokine secretion by Th17 cells. 
30 
CD4
+
 T cells were cultured for four days under Th17-differentiation conditions. In a) 
and b), cells were reactivated for 24h with anti-CD3 antibodies in the presence (closed 
squares) or absence (open squares) of anti-ICOS antibodies as a costimulus, or left 
unstimulated (open triangles). PI3K inhibitors (p110/p110, ETP-46321; p110, A66; 
p110, IC87114) were added, as indicated. After overnight culture, supernatants were 
analyzed by ELISA for a) IL-17A, and b) IL-21 content. c) Th17 cells were reactivated 
for 24h with anti-CD3 antibodies plus anti-ICOS antibodies in the presence of PI3K 
inhibitors (p110/p110, ETP-46321; p110, A66; p110, IC87114), as indicated. 
Black triangles indicate data from cultures receiving A66 plus IC87114 (p110 + 
p110). Data are the mean ± SEM of triplicate samples from one representative 
experiment of four performed; *, significant differences (p <0.05, Student’s t-test) with 
control cultures with vehicle.  
 
Figure 4. Effect of ICOS and PI3-kinases on early signals, IL-17A, and IL-21 
secretion by Tfh cells. 
CD4
+
 T cells were cultured for four days under Tfh-differentiation conditions. Then, a) 
Tfh cells were activated for 20 min with anti-CD3 antibodies in the presence or absence 
of anti-ICOS antibodies, and phosphorylation of Akt (pSer
473
Akt (top); pThr
308
Akt 
(middle)), or Erk (pErk, bottom) was determined in cell lysates by immunoblot. Anti-
Akt or anti-Erk antibodies were used for loading controls, as shown in the figure. Where 
indicated, 1 M PI3K inhibitors (p110/p110, ETP-46321 (/); p110, A66 (); 
p110, IC87114 ()) were added. The relative O.D. in each lane is plotted in the right 
panels. *, significant differences with samples in lane 3 (p <0.05, Student’s t-test). 
b) Tfh cells were reactivated overnight with anti-CD3 plus anti-ICOS antibodies (closed 
symbols) or anti-CD3 antibody alone (open squares). PI3K inhibitors (p110/, ETP-
46321; p110, A66; p110, IC87114) or vehicle were added as indicated in the figure. 
Culture supernatants were analyzed for IL-17A or IL-21 content by ELISA. Data are the 
mean ± SEM of triplicate samples from one representative experiment of four 
performed; *, significant differences with control cultures with vehicle (p <0.05, 
Student’s t-test). 
 
Figure 5. Effect of ETP-46321 administration “in vivo” on KLH-specific antibody 
and cytokine responses. 
31 
a) Mice (n=5 per group) were immunized with KLH on day 0; ETP-46321 (20 mg kg
-1
) 
was administered p.o. four days beginning the third day after immunization and 
sacrificed the next day, as indicated. 
b) Serum was obtained on day 7 and individually analyzed for KLH-specific antibodies 
of the IgM, IgG1, IgG2b, and IgG3 subclasses. 
c) Cells from the draining lymph nodes of the same mice (n=5 per group) were obtained 
on day 7 and reactivated with KLH for three days “in vitro”. Then, cell growth was 
determined by a colorimetric assay using MTT (left panel), and IL-2, IL-4, IL-10, IL-
17A, and IFN- in culture supernatants was determined by ELISA, as indicated. *, 
significant differences between samples from different mice (p <0.05, Mann Whitney 
test). N.S.: Non significant. 
 
Figure 6. Administration of the PI3K p110/ inhibitor ETP-46321 inhibits 
collagen-induced arthritis and collagen-specific immune responses. 
a) Mice were immunized with chicken type II collagen; appearance of clinical 
symptoms of arthritis was assessed daily and scored in each limb, as follows: 0 normal, 
1 slight swelling and erythema, 2 pronounced edematous swelling, 3 joint rigidity 
(maximum possible score of 12 per mouse). Upon appearance of clinical symptoms 
(clinical score ≥1) each mouse was randomly assigned to treatment with vehicle or 
ETP-46321 (20 mg kg
-1
) p.o. for 11 days (Vehicle n=9; ETP-46321 n=10). Data 
represents the mean ±SE for each experimental group. *, significant differences 
between samples (p <0.05). 
b) Mice immunized with chicken type II collagen and treated with vehicle or ETP-
46321 (20 mg kg
-1
) p.o. 11 days, as described in a). On day 12 after initiation of 
treatment, mice were bled and the serum from each mouse was individually analyzed 
for whole IgG collagen-II-specific antibodies, or the clinically relevant IgG1 and IgG2a 
subclasses (Vehicle n=7; ETP-46321 n=6). 
c) Cells from the draining lymph nodes of each treated mice described in b) were 
individually activated "in vitro" with type II chicken collagen II (Vehicle n=7; ETP-
46321 n=6). After 72 h of culture, supernatants were taken and antigen-specific 
proliferation determined by a colorimetric assay using WST-1. Secreted IL-17A and 
IFN- was determined by ELISA. *, significant differences between samples (p <0.05); 
N.S.: Non significant. 
 Table 1. IC50 values (nM) of PI3K inhibitors for catalytic activity of different PI3K isoforms. 
 
 p110 p110 p110 p110 mTORC1/C2 
A66 () 32.0 20 000.0 18 050.0 18 810.0  
IC87114 () >100 000.0 1 820.0 70.0 1 240.0  
ETP-46321 (,) 2.4 549.0 14.0 153.0 >5 000.0 
LY294002 (Broad) 700.0 306.0 1 330.0 7 260.0 8 910.0 
 
Data compiled from references [17-19, 25, 26] and [27-29]. 
 
 
 
 
  
Table 2. Cytokine secretion by CD4
+
 T cells: Sensitivity to PI3-K inhibitors 
 
Inhibitor  IC50 (M) 
(Specificity) Cells IL-2 IL-4 IL-10 IL-17A IL-21 IFN- 
ETP-46321 
Naive CD4
+
 T 
cells 
(a)
 
0.70  >5.00   0.07 
(p110/) 
T CD4
+
 IL-2 
Blasts 
(b)
 
0.20 0.10 5.00 1.00 n.d.
(c)
  0.20 
 Th17 Cells 
(b)
    0.20 2.50  
 Tfh Cells 
(b)
    0.20 0.90  
A66 
Naive CD4
+
 T 
cells 
(a)
 
5.00  >10.00   1.00 
(p110) 
T CD4
+
 IL-2 
Blasts 
(b)
 
2.00 2.20 >10.00 5.00 n.d.
(c)
 3.20 
 Th17 Cells 
(b)
    2.50 >10.00  
 Tfh Cells 
(b)
    3.50 >10.00  
IC87114 
Naive CD4
+
 T 
cells 
(a)
 
3.50  >10.00   0.06 
(p110) 
T CD4
+
 IL-2 
Blasts 
(b)
 
0.10 0.07 >10.00 5.00 n.d.
(c)
 0.10 
 Th17 Cells 
(b)
    1.00 >10.00  
 Tfh Cells 
(b)
    0.80 >10.00  
 
.(a)
 Activated 24h by anti-CD3 plus anti-CD28 antibodies. 
.(b)
 Activated 24h by anti-CD3 plus anti-ICOS antibodies. 
(c)
 n.d.: Not detected in these cells 
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Figure 2. Activation of T CD4+ blasts
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Figure 03. Effect of ICOS and PI3-K inhibitors on CD3 activation of cytokine
secretion by Th17 cells.
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Figure 04. Effect of ICOS and ETP-46321 on CD3 activation of Tfh cells. a) 
Early Akt and Erk phosphorylation; b) IL-17A and IL-21 secretion.
a) Tfh: Akt and Erk phosphorylation
b) Tfh: IL-17A and IL-21 secretion
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Figure 05. Effect of ETP-46321 administration “in vivo” on antibody and 
cytokine responses to KLH.
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Figure 06. Effect of ETP-46321 administration “in vivo” on collagen-induced
arthritis and anti-collagen response.
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Figure 1S.  Activation of T CD4+ naive lymphocytes (72h). 
Naïve  CD4+ T cells (CD4+CD62L+) cells (106) were cultured in 1 ml culture 
medium in 24-well culture plates (Costar) pre-coated with anti-CD3 antibody 
(YCD3-1 5 g ml-1). Where indicated, anti-CD28 (H57, eBiosciences, 2.5 g ml-1), 
DMSO or inhibitors dissolved in DMSO (1 l per culture) were added. At 72h, the 
cultures were resuspended, centrifuged and the supernatants taken. a) The cells were 
suspended in fresh culture medium and assayed for live cells using MTT . The 
supernatants were checked for  b) IL-2, c) IL-10, or d) IFN-g content. 
